niacin

Summary

Summary: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.

Top Publications

  1. ncbi First-line therapies for lowering triglyceride levels
    Vasudevan A Raghavan
    Am Fam Physician 77:416; author reply 417-8. 2008
  2. ncbi Extended-release niacin or ezetimibe and carotid intima-media thickness
    Allen J Taylor
    Cardiology Service, Walter Reed Army Medical Center, Washington, DC, USA
    N Engl J Med 361:2113-22. 2009
  3. ncbi Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors
    M John Chapman
    INSERM, UMR S939, Dyslipidemia, Inflammation and Atherosclerosis Research Unit, University Pierre and Marie Curie Paris 6, Pavillon Benjamin Delessert, Hopital de la Pitie, 83 Boulevard de l hopital, Paris Cedex 13, France
    Eur Heart J 31:149-64. 2010
  4. ncbi Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy
    Sajoscha A Sorrentino
    Klinik für Kardiologie und Angiologie, Medizinische Hochschule Hannover, Hannover, Germany
    Circulation 121:110-22. 2010
  5. ncbi Niacin bound chromium treatment induces myocardial Glut-4 translocation and caveolar interaction via Akt, AMPK and eNOS phosphorylation in streptozotocin induced diabetic rats after ischemia-reperfusion injury
    Suresh Varma Penumathsa
    Molecular Cardiology and Angiogenesis Laboratory, Department of Surgery, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030 1110, USA
    Biochim Biophys Acta 1792:39-48. 2009
  6. ncbi Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib
    Laurent Yvan-Charvet
    Division of Molecular Medicine, Department of Medicine, Columbia University, 630 W 168th St, New York, NY 10032, USA
    Arterioscler Thromb Vasc Biol 30:1430-8. 2010
  7. ncbi Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study
    Justin M S Lee
    Department of Cardiovascular Medicine, University of Oxford and Oxford Centre for Clinical Magnetic Resonance Research OCMR, Oxford, United Kingdom
    J Am Coll Cardiol 54:1787-94. 2009
  8. ncbi Molecular identification of high and low affinity receptors for nicotinic acid
    Alan Wise
    Department of 7TMR Systems Research, GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, United Kingdom
    J Biol Chem 278:9869-74. 2003
  9. ncbi Langerhans cells release prostaglandin D2 in response to nicotinic acid
    Dominique Maciejewski-Lenoir
    Arena Pharmaceuticals Inc, San Diego, California 92121, USA
    J Invest Dermatol 126:2637-46. 2006
  10. ncbi Effect of niacin on LXRalpha and PPARgamma expression and HDL-induced cholesterol efflux in adipocytes of hypercholesterolemic rabbits
    Shui Ping Zhao
    Department of Cardiology, The Second Xiangya Hospital of Central South University, Middle Ren Min Road No 86, Changsha, Hunan 410011, PR China
    Int J Cardiol 124:172-8. 2008

Research Grants

  1. Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis
    Emmanouil Brilakis; Fiscal Year: 2010
  2. Aromatic amino acid metabolism in the pathogenesis of kwashiorkor
    Farook Jahoor; Fiscal Year: 2007
  3. LIPOGENESIS & LIPOPROTEIN COMPLICATIONS OF HIV THERAPY
    David Hui; Fiscal Year: 2004
  4. Discovery and Preclinical Development of Drugs for Anthrax, Plague and Tularemia
    Christie Brouillette; Fiscal Year: 2007
  5. Comprehensive Magnetic Resonance in PAD
    Christopher M Kramer; Fiscal Year: 2010
  6. OMEGA-3 FATTY ACIDS IN BIPOLAR DISORDER PROPHYLAXIS
    ANDREW STOLL; Fiscal Year: 2002
  7. MECHANISMS OF ENZYMATIC REACTIONS
    PERRY FREY; Fiscal Year: 2002
  8. HDL AND PLAQUES--NOVEL MODELS AND IMAGING TECHNIQUES
    Edward Fisher; Fiscal Year: 2001
  9. Niacin, n-3 fatty acids and insulin resistance
    William Harris; Fiscal Year: 2006
  10. Niacin, n-3 fatty acids and insulin resistance
    William Harris; Fiscal Year: 2007

Detail Information

Publications232 found, 100 shown here

  1. ncbi First-line therapies for lowering triglyceride levels
    Vasudevan A Raghavan
    Am Fam Physician 77:416; author reply 417-8. 2008
  2. ncbi Extended-release niacin or ezetimibe and carotid intima-media thickness
    Allen J Taylor
    Cardiology Service, Walter Reed Army Medical Center, Washington, DC, USA
    N Engl J Med 361:2113-22. 2009
    ....
  3. ncbi Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors
    M John Chapman
    INSERM, UMR S939, Dyslipidemia, Inflammation and Atherosclerosis Research Unit, University Pierre and Marie Curie Paris 6, Pavillon Benjamin Delessert, Hopital de la Pitie, 83 Boulevard de l hopital, Paris Cedex 13, France
    Eur Heart J 31:149-64. 2010
    ..e. statins, fibrates, and niacin, and compares their mechanisms of action with those of pharmacological agents under development which directly ..
  4. ncbi Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy
    Sajoscha A Sorrentino
    Klinik für Kardiologie und Angiologie, Medizinische Hochschule Hannover, Hannover, Germany
    Circulation 121:110-22. 2010
    ..Moreover, in diabetic patients, we examined the impact of extended-release (ER) niacin therapy on the endothelial effects of HDL.
  5. ncbi Niacin bound chromium treatment induces myocardial Glut-4 translocation and caveolar interaction via Akt, AMPK and eNOS phosphorylation in streptozotocin induced diabetic rats after ischemia-reperfusion injury
    Suresh Varma Penumathsa
    Molecular Cardiology and Angiogenesis Laboratory, Department of Surgery, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030 1110, USA
    Biochim Biophys Acta 1792:39-48. 2009
    ..We investigated the effect of niacin-bound chromium (NBC) during ischemia/reperfusion (IR) injury in streptozotocin induced diabetic rats...
  6. ncbi Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib
    Laurent Yvan-Charvet
    Division of Molecular Medicine, Department of Medicine, Columbia University, 630 W 168th St, New York, NY 10032, USA
    Arterioscler Thromb Vasc Biol 30:1430-8. 2010
    To examine the effects of treatments with niacin or anacetrapib (an inhibitor of cholesteryl ester transfer protein) on the ability of high-density lipoprotein (HDL) to promote net cholesterol efflux and reduce toll-like receptor-mediated ..
  7. ncbi Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study
    Justin M S Lee
    Department of Cardiovascular Medicine, University of Oxford and Oxford Centre for Clinical Magnetic Resonance Research OCMR, Oxford, United Kingdom
    J Am Coll Cardiol 54:1787-94. 2009
    ..Our aim was to determine the effects of high-dose (2 g) nicotinic acid (NA) on progression of atherosclerosis and measures of vascular function...
  8. ncbi Molecular identification of high and low affinity receptors for nicotinic acid
    Alan Wise
    Department of 7TMR Systems Research, GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, United Kingdom
    J Biol Chem 278:9869-74. 2003
    ..The discovery of HM74A as a molecular target for nicotinic acid may facilitate the discovery of superior drug molecules to treat dyslipidemia...
  9. ncbi Langerhans cells release prostaglandin D2 in response to nicotinic acid
    Dominique Maciejewski-Lenoir
    Arena Pharmaceuticals Inc, San Diego, California 92121, USA
    J Invest Dermatol 126:2637-46. 2006
    ..These results suggest that nicotinic acid mediates its flushing side effect by interacting with GPR109A on skin Langerhans cells, resulting in release of PGD(2)...
  10. ncbi Effect of niacin on LXRalpha and PPARgamma expression and HDL-induced cholesterol efflux in adipocytes of hypercholesterolemic rabbits
    Shui Ping Zhao
    Department of Cardiology, The Second Xiangya Hospital of Central South University, Middle Ren Min Road No 86, Changsha, Hunan 410011, PR China
    Int J Cardiol 124:172-8. 2008
    ..The aim of this study was to evaluate the effect of niacin on LXRalpha and PPARgamma expression and HDL-induced cholesterol efflux in adipocytes from hypercholesterolemic ..
  11. ncbi Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia
    Klaus G Parhofer
    Medical Department II Grosshadern, University of Munich, Germany
    Vasc Health Risk Manag 5:901-8. 2009
    ..b>Niacin (nicotinic acid) is an effective drug which increases the plasma concentration of high-density lipoprotein (HDL)-..
  12. ncbi beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice
    Robert W Walters
    Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
    J Clin Invest 119:1312-21. 2009
    ..Furthermore, G protein-biased ligands that activate GPR109A in a beta-arrestin-independent fashion may represent an improved therapeutic option for the treatment of dyslipidemia...
  13. ncbi Nicotinic acid induces secretion of prostaglandin D2 in human macrophages: an in vitro model of the niacin flush
    C Daniel Meyers
    Long Beach Veterans Affairs Healthcare System, Long Beach, CA, United States
    Atherosclerosis 192:253-8. 2007
    ..shown to prevent cardiovascular disease, yet its widespread use is limited by the prostaglandin D2 (PGD2) mediated niacin flush...
  14. ncbi Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids
    Ben J Wu
    Lipid Research Group, Heart Research Institute, 7 Eliza St, Newtown, New South Wales, Australia 2042
    Arterioscler Thromb Vasc Biol 30:968-75. 2010
    To determine if niacin can confer cardiovascular benefit by inhibiting vascular inflammation and improving endothelial function independent of changes in plasma lipid and lipoprotein levels.
  15. ncbi Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease
    Jasleen K Duggal
    Chicago Medical School and Affiliated Hospitals, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA
    J Cardiovasc Pharmacol Ther 15:158-66. 2010
    b>Niacin or nicotinic acid (vitamin B3) raises the levels of high-density lipoprotein cholesterol (HDL) by about 30% to 35%...
  16. ncbi Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2
    Allen J Taylor
    Cardiology Service, Walter Reed Army Medical Center, 6900 Georgia Avenue, NW, Building 2, Room 4A34, Washington, DC 20307 5001, USA
    Vasc Health Risk Manag 3:159-64. 2007
    We previously reported in a placebo-controlled study that extended-release niacin slowed the progression of carotid atherosclerosis when added to statin monotherapy...
  17. ncbi Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia
    S Shah
    Merck Research Laboratories, Cardiovascular Disease, Merck, Sharp and Dohme Corp, Rahway, NJ 07065, USA
    Int J Clin Pract 64:727-38. 2010
    Co-administration of niacin with statin offers the potential for additional lipid management and cardiovascular risk reduction...
  18. ncbi Safety and toxicological evaluation of a novel niacin-bound chromium (III) complex
    Michael Shara
    Creighton University Medical Center, Omaha, NE, USA
    J Inorg Biochem 99:2161-83. 2005
    ..It also helps in energy production and increasing lean body mass. Niacin-bound chromium (NBC) is a unique form of bioavailable chromium that promotes healthy lipid profile...
  19. ncbi Nicotinic acid: pharmacological effects and mechanisms of action
    Andreas Gille
    Institute of Pharmacology, University of Heidelberg, Heidelberg, Germany
    Annu Rev Pharmacol Toxicol 48:79-106. 2008
    ....
  20. ncbi Combined statin and niacin therapy remodels the high-density lipoprotein proteome
    Pattie S Green
    Department of Medicine, University of Washington, Seattle, WA, USA
    Circulation 118:1259-67. 2008
    ..We hypothesized that an intervention that increases HDL levels-combined statin and niacin therapy-might reverse these changes.
  21. ncbi Niacin lowers serum phosphate and increases HDL cholesterol in dialysis patients
    Daniela Muller
    Franz Volhard Clinic, Department of Nephrology and Hypertension, Medical Faculty of the Charite, HELIOS Klinikum Berlin, Berlin, Germany
    Clin J Am Soc Nephrol 2:1249-54. 2007
    ..Adverse effects complicate the use of drugs that are prescribed for phosphate control in dialysis patients. Alternative treatment options are needed...
  22. ncbi Hemodynamic effects of nicotinic acid infusion in normotensive and hypertensive subjects
    Crystal A Gadegbeku
    Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA
    Am J Hypertens 16:67-71. 2003
    ..The adjustment in vascular compliance may be an important factor in determining overall BP response to NA...
  23. ncbi Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins
    Allen J Taylor
    Cardiovascular Research, Cardiology Service, Walter Reed Army Medical Center, 6900 Georgia Ave, NW, Bldg 2, Room 3L28, Washington, DC 20307 5001, USA
    Circulation 110:3512-7. 2004
    b>Niacin reduces coronary heart disease morbidity and mortality when taken either alone or in combination with statins; however, the incremental impact of adding niacin to background statin therapy is unknown.
  24. ncbi Biochemical assessment of niacin deficiency among carcinoid cancer patients
    Girish M Shah
    Laboratory for Skin Cancer Research, CHUL Research Center (CHUQ, Faculty of Medicine, Laval University, Sainte-Foy, Quebec, Canada
    Am J Gastroenterol 100:2307-14. 2005
    ..fraction of tryptophan catabolism, which should be directed along a pathway that allows partial conversion to niacin; hence, increased diversion of tryptophan toward serotonin could cause variable degrees of niacin deficiency in ..
  25. ncbi Treatment with niacin lowers ADMA
    Sabine Westphal
    Atherosclerosis 184:448-50. 2006
  26. ncbi Niacin and carcinogenesis
    James B Kirkland
    Department of Human Biology and Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada
    Nutr Cancer 46:110-8. 2003
    The dietary status of niacin (vitamin B3) has the potential to influence DNA repair, genomic stability, and the immune system, eventually having an impact on cancer risk, as well as the side effects of chemotherapy in the cancer patient...
  27. ncbi Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels
    David M Capuzzi
    Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    Am J Cardiol 91:1304-10. 2003
    ..and low high-density lipoprotein (HDL) cholesterol levels may benefit from combination therapy with a statin and niacin; therefore, we assessed the efficacy and safety of rosuvastatin and extended-release (ER) niacin alone and in ..
  28. ncbi Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events
    Michael H Davidson
    Department of Preventive Cardiology, Rush-Presbyterian-St. Luke's Medical Center, 1725 West Harrison Street, Chicago, IL 60612, USA
    Curr Atheroscler Rep 5:418-22. 2003
  29. ncbi Decreasing the oxidant stress from paraquat in isolated perfused rat lung using captopril and niacin
    Mahmoud Ghazi-Khansari
    Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, P O Box 13145 784, Tehran, Iran
    Arch Toxicol 79:341-5. 2005
    The abilities of captopril and niacin to protect against the lung toxicity of paraquat (PQ) were studied...
  30. ncbi Clinical inquiries. Should liver enzymes be checked in a patient taking niacin?
    Gloria S Rizakallah
    St Louis College of Pharmacy and Mercy Family Medicine, St Louis, MO USA
    J Fam Pract 54:265-8. 2005
  31. ncbi Comparison of rat and dog models of vasodilatation and lipolysis for the calculation of a therapeutic index for GPR109A agonists
    Ester Carballo-Jane
    Department of Pharmacology, Merck Research Laboratories, Rahway, NJ, USA
    J Pharmacol Toxicol Methods 56:308-16. 2007
    ..The rat and the dog have previously been used to study the antilipolytic effects of nicotinic acid, but no optimal vasodilatation model exits in either species...
  32. ncbi Effect of lipid-lowering drug therapy on small-dense low-density lipoprotein
    James M Backes
    Department of Pharmacy Practice, School of Pharmacy, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160 7231, USA
    Ann Pharmacother 39:523-6. 2005
    ..To review the effects of lipid-lowering therapy on small-dense low-density lipoprotein cholesterol (sdLDL-C)...
  33. ncbi Beneficial effects of combined treatment with niacin and chromium on the liver of hyperlipemic rats
    Sema Bolkent
    Department of Medical Biology, Cerrahpasa Faculty of Medicine, Istanbul University, 34300-Cerrahpasa, Istanbul, Turkey
    Biol Trace Elem Res 101:219-29. 2004
    Many studies have shown that niacin and Cr exert combined effects. Significant beneficial effects in serum lipid levels following Cr supplementation have been reported...
  34. ncbi Long-term safety evaluation of a novel oxygen-coordinated niacin-bound chromium (III) complex
    Michael Shara
    Creighton University Medical Center, Omaha, NE, USA
    J Inorg Biochem 101:1059-69. 2007
    ..including in vitro, in vivo and clinical studies demonstrated the beneficial effects of novel oxygen- coordinated niacin-bound chromium (III) complex (NBC) in promoting glucose-insulin sensitivity, lipid profile, cardioprotective ..
  35. ncbi Extended-release niacin for modifying the lipoprotein profile
    John R Guyton
    Duke University Medical Center, Department of Medicine, Durham, North Carolina, USA
    Expert Opin Pharmacother 5:1385-98. 2004
    b>Niacin (nicotinic acid) favourably modifies all aspects of the lipoprotein profile; it raises high-density lipoprotein cholesterol (HDL-C) levels, lowers triglyceride, low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) levels ..
  36. ncbi A topical lipophilic niacin derivative increases NAD, epidermal differentiation and barrier function in photodamaged skin
    Elaine L Jacobson
    Department of Pharmacology and Toxicology, College of Pharmacy, Tucson, AZ 85724, USA
    Exp Dermatol 16:490-9. 2007
    ....
  37. ncbi Niacin nutritional status in HIV type 1-positive children: preliminary data
    Marina Hjertquist Tremeschin
    Medical School of Ribeirao Preto, University of Sao Paulo, Sao Paulo, Brazil
    J Pediatr Gastroenterol Nutr 44:629-33. 2007
    ..This study compared the nutritional status and the 24-hour urine excretion of N-methylnicotinamide between HIV-positive children and HIV-negative children who were or were not born of mothers with HIV-1 infection...
  38. ncbi The effects of niacin on lipoprotein subclass distribution
    John M Morgan
    Thomas Jefferson University, Jefferson Heart Institute, Sidney Kimmel Laboratory for Preventive Medicine, 925 Chestnut Street, 1st Floor, Philadelphia, PA 19107, USA
    Prev Cardiol 7:182-7; quiz 188. 2004
    ..b>Niacin has long been known to improve concentrations of all major lipids and lipoproteins, but it also has consistently ..
  39. ncbi Niacin therapy in atherosclerosis
    C Daniel Meyers
    Endocrinology Section, VA Long Beach Healthcare System, Department of Medicine, University of California, Irvine, California, USA
    Curr Opin Lipidol 15:659-65. 2004
    PURPOSE OF REVIEW: Well designed, randomized, placebo-controlled studies show that niacin prevents cardiovascular disease and death...
  40. ncbi Niacin ameliorates oxidative stress, inflammation, proteinuria, and hypertension in rats with chronic renal failure
    Kyu hyang Cho
    Division of Nephrology and Hypertension, University of California, Irvine, California, USA
    Am J Physiol Renal Physiol 297:F106-13. 2009
    ..b>Niacin is known to improve lipid metabolism and exert antioxidant/anti-inflammatory actions...
  41. ncbi Protective effects of a novel niacin-bound chromium complex and a grape seed proanthocyanidin extract on advancing age and various aspects of syndrome X
    Harry G Preuss
    Department of Physiology, Georgetown University Medical Center, Washington, D C 20007, USA
    Ann N Y Acad Sci 957:250-9. 2002
    ..Accordingly, ingestion of niacin-bound chromium and natural antioxidants such as grape seed proanthocyanidin extract has been demonstrated to ..
  42. ncbi Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects
    Eseng Lai
    Merck Research Laboratories, Rahway, NJ 07065, USA
    Platelets 21:191-8. 2010
    Laropiprant (LRPT) has been shown to reduce flushing symptoms induced by niacin and has been combined with niacin for treatment of dyslipidemia...
  43. ncbi Niacin and laropiprant
    S Sanyal
    Division of Cardiology, Department of Medicine, Preventive Cardiology Center, Tufts Medical Center, Boston, MA 02111, USA
    Drugs Today (Barc) 46:371-8. 2010
    Nicotinic acid (niacin) is one of the oldest drugs used to treat dyslipidemia...
  44. ncbi Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk
    M John Chapman
    Dyslipidemia, Inflammation and Atherosclerosis Research Unit, UMR S939, National Institute for Health and Medical Research INSERM, Hopital de la Pitie Salpetriere, Paris, France
    Pharmacol Ther 126:314-45. 2010
    ..In this context, there is renewed interest in pharmacotherapeutic strategies involving niacin and fibrates in monotherapy and in association with statins...
  45. ncbi Niacin-induced "flush" involves release of prostaglandin D2 from mast cells and serotonin from platelets: evidence from human cells in vitro and an animal model
    Dean Papaliodis
    Department of Pharmacology and Experimental Therapeutics, Molecular Immunopharmacology and Drug Discovery Laboratory, Tufts University School of Medicine, Tufts Medical Center, Boston, MA 02111, USA
    J Pharmacol Exp Ther 327:665-72. 2008
    b>Niacin lowers serum cholesterol, low-density lipoprotein, and triglycerides, and it raises high-density lipoprotein. However, most patients experience cutaneous warmth and vasodilation (flush)...
  46. ncbi Does nicotinic acid (niacin) lower blood pressure?
    H E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY40213, USA
    Int J Clin Pract 63:151-9. 2009
    Nicotinic acid (niacin) is a well-established treatment for dyslipidaemia - an important cardiovascular disease (CVD) risk factor. However, niacin may also reduce blood pressure (BP), which is another important CVD risk factor...
  47. ncbi SIRT1 genetic variation and mortality in type 2 diabetes: interaction with smoking and dietary niacin
    M Carola Zillikens
    Department of Internal Medicine, Erasmus Medical Center, 3000 CA Rotterdam, The Netherlands
    Free Radic Biol Med 46:836-41. 2009
    SIRT1 protects cells against oxidative stress and aging. Its activity may be modulated by dietary niacin (vitamin B3) intake...
  48. ncbi Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease
    Darbie Maccubbin
    Merck Research Laboratories, Rahway, NJ, USA
    Am J Cardiol 104:74-81. 2009
    b>Niacin has beneficial effects on a patient's lipid and lipoprotein profiles and cardiovascular risk, particularly at doses >2 g/day, but is underused due to flushing...
  49. ncbi Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center Inc, Louisville, Kentucky, USA
    Clin Ther 31:115-22. 2009
    Dyslipidemia and high blood pressure are both major cardiovascular disease risk factors. Niacin is an effective lipid-altering agent that has been reported to reduce the risk of cardiovascular disease...
  50. ncbi Nicotinic acid and the prevention of coronary artery disease
    Janet E Digby
    Department of Cardiovascular Medicine, University of Oxford, Oxford, UK
    Curr Opin Lipidol 20:321-6. 2009
    ..at all levels of LDL cholesterol has, therefore, given renewed emphasis on the therapeutic potential of niacin. The purpose of this review is to evaluate advances in the elucidation of mechanisms by which nicotinic acid ..
  51. ncbi Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1500 mg
    Jin Wi
    Cardiology Division, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
    Atherosclerosis 213:235-40. 2010
    ..However, an optimal pharmacologic approach has not yet been established. The aim of this study is to compare the efficacy and tolerability of the typical doses of fenofibrate and niacin.
  52. ncbi High-affinity transporters for NAD+ precursors in Candida glabrata are regulated by Hst1 and induced in response to niacin limitation
    Biao Ma
    Department of Molecular Biology and Genetics, Johns Hopkins School of Medicine, 725 North Wolfe Street, Baltimore, MD 21205 2185, USA
    Mol Cell Biol 29:4067-79. 2009
    ..C. glabrata is a NAD(+) auxotroph, and its growth depends on the availability of niacin (environmental vitamin precursors of NAD(+))...
  53. ncbi Niacin status and treatment-related leukemogenesis
    James B Kirkland
    University of Guelph, Guelph, Ontario, Canada, N1G 2W1
    Mol Cancer Ther 8:725-32. 2009
    ..b>Niacin deficiency, which is common in cancer patients, causes dramatic genomic instability in bone marrow cells in an in ..
  54. ncbi Combined effects of niacin and chromium treatment on vascular endothelial dysfunction in hyperlipidemic rats
    N Niu
    Department of Pediatrics, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, 250021, China
    Mol Biol Rep 36:1275-81. 2009
    Combined treatment with niacin and chromium has been found to have a protective effect against oxidative damage to different tissues of hyperlipidemic rats. But its effects on vascular endothelial dysfunction are less clear...
  55. ncbi Niacin's role in the statin era
    Erica L Brooks
    Preventive Cardiology Center, Tufts Medical Center, Division of Cardiology, Department of Medicine, 800 Washington Street, Box 80, Boston, MA 02111, USA
    Expert Opin Pharmacother 11:2291-300. 2010
    The combination use of niacin and HMG Co-A reductases (statins) is increasing. While statin therapy reduces the risk of adverse cardiovascular events, additional therapies are needed to decrease event rates further...
  56. ncbi Seeing red: flushing out instigators of niacin-associated skin toxicity
    Richard L Dunbar
    Department of Medicine, Division of Experimental Therapeutics, Institute for Translational Medicine and Therapeutics, Pennsylvania 19104, USA
    J Clin Invest 120:2651-5. 2010
    The use of niacin to improve plasma lipid levels and reduce risk of myocardial infarction is limited by noxious skin effects that result from stimulation of G protein-coupled receptor 109A (GPR109A) in skin immune cells...
  57. ncbi Postprandial triglyceride responses to aerobic exercise and extended-release niacin
    Eric P Plaisance
    Department of Kinesiology, Auburn University, Auburn, AL, USA
    Am J Clin Nutr 88:30-7. 2008
    Aerobic exercise and niacin are frequently used strategies for reducing serum triglycerides, and, yet, there is no information regarding the combined effects of these strategies on postprandial triglycerides.
  58. ncbi Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease
    Anders G Olsson
    Department of Medicine and Health, Linkoping University, SE 58183 Linkoping, Sweden
    Expert Opin Pharmacother 11:1715-26. 2010
    ..The best drug available for that purpose is niacin. In addition to increasing HDL cholesterol and apolipoprotein A1, niacin decreases triglycerides, low-density ..
  59. ncbi Niacin treatment of stroke increases synaptic plasticity and axon growth in rats
    Xu Cui
    Department of Neurology, Henry Ford Hospital, Detroit, Mich 48202, USA
    Stroke 41:2044-9. 2010
    b>Niacin is the most effective medication in current clinical use for increasing high-density lipoprotein cholesterol...
  60. ncbi Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial
    Darbie Maccubbin
    Rhode Island Hospital, Division of Kidney Diseases and Hypertension, 593 Eddy Street, Providence, RI, 02903, USA
    Clin J Am Soc Nephrol 5:582-9. 2010
    b>Niacin administration lowers the marked hyperphosphatemia that is characteristic of renal failure...
  61. ncbi The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3
    Allen J Taylor
    Cardiology Service, Walter Reed Army Medical Center, Washington, DC 20307 5001, USA
    Curr Med Res Opin 22:2243-50. 2006
    The ARBITER 2 trial showed that extended-release niacin (ERN) when added to statin monotherapy slowed the progression of carotid atherosclerosis over 12 months...
  62. ncbi Negative correlation between cerebral inorganic phosphate and the volumetric niacin response in male patients with schizophrenia who have seriously and dangerously violently offended: a (31)P magnetic resonance spectroscopy study
    B K Puri
    MRI Unit, Imaging Sciences Department, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Hospital, London, UK
    Prostaglandins Leukot Essent Fatty Acids 77:97-9. 2007
    ..Spectra were obtained from 70 x 70 x 70 mm(3) voxels using an image-selected in vivo spectroscopy pulse sequence. Niacin flush testing results were quantified as the volumetric niacin response...
  63. ncbi Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project)
    Paul L Canner
    Maryland Medical Research Institute, Baltimore, Maryland, USA
    Am J Cardiol 97:477-9. 2006
    This post hoc analysis from the Coronary Drug Project (CDP) evaluated the effects of niacin monotherapy on clinical outcomes in patients with and without the metabolic syndrome (MS)...
  64. ncbi Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance
    Axel Linke
    Department of Cardiology, Heart Center, University of Leipzig, Leipzig, Germany
    Atherosclerosis 205:207-13. 2009
    ..Extended-release (ER) niacin increases HDL-C and was shown to slow the progression of atherosclerosis...
  65. ncbi 2nd International Symposium on Triglycerides and HDL: lipid abnormalities and their treatment
    Zachary T Bloomgarden
    Division of Endocrinology, Mount Sinai School of Medicine, New York, NY, USA
    Diabetes Care 28:2795-802. 2005
  66. ncbi Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome
    Richard W Nesto
    Department of Cardiovascular Medicine, Lahey Clinic, Burlington, Massachusetts 02493, USA
    Am J Cardiovasc Drugs 5:379-87. 2005
    ....
  67. ncbi Modifying plasma low-density lipoprotein and high-density lipoprotein cholesterol: what combinations are available in the future?
    John J P Kastelein
    Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Am J Cardiol 96:20K-27K; discussion 34K-35K. 2005
    ..Management of the metabolic syndrome focusing on the modification of plasma LDL as well as high-density lipoprotein cholesterol is reviewed. Future management strategies with the use of novel combination therapy is also discussed...
  68. ncbi Management of hyperlipidemia: new LDL-C targets for persons at high-risk for cardiovascular events
    Ebrahim A Balbisi
    Department of Clinical Pharmacy Practice, College of Pharmacy and Allied Health Professions, St John s University, New York, NY, USA
    Med Sci Monit 12:RA34-9. 2006
    ..In spite of the challenges, there are ample opportunities for improving the management of hyperlipidemia. Adherence to the recommendations will vastly reduce morbidity and mortality associated with CHD...
  69. ncbi Adherence and persistence with single-dosage form extended-release niacin/lovastatin compared with statins alone or in combination with extended-release niacin
    Joanne LaFleur
    Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, 84108, USA
    Ann Pharmacother 40:1274-9. 2006
    ..A fixed-dose combination product, extended-release niacin/lovastatin (ERNL), has been shown to be beneficial in lipid management; however, little is known regarding patient ..
  70. ncbi Nicotinic acid and other therapies for raising high-density lipoprotein
    Lars A Carlson
    Karolinska Institutet, King Gustaf V Research Institute, Stockholm, Sweden
    Curr Opin Cardiol 21:336-44. 2006
    ..Other treatments for raising high-density lipoprotein, including changes in lifestyle, other drugs and infusions of 'synthetic' (reconstituted) high-density lipoprotein will be summarized...
  71. ncbi Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center and University of Oklahoma School of Medicine, Oklahoma City, 73132 4904, USA
    J Clin Hypertens (Greenwich) 8:493-9; quiz 500-1. 2006
    ..b>Niacin, on the other hand, is the most potent drug available for lowering plasma levels of triglycerides and lipoprotein(..
  72. ncbi [Treatment of dyslipidemia: how and when to combine lipid lowering drugs]
    Isio Schulz
    Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP
    Arq Bras Endocrinol Metabol 50:344-59. 2006
    ..Association of statin/niacin seems be very useful in patients with FCH, especially as niacin is the best drug to increase HDL cholesterol; this ..
  73. ncbi Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia
    John F Paolini
    Merck Research Laboratories, Rahway, NJ, USA
    Am J Cardiol 101:625-30. 2008
    b>Niacin (nicotinic acid) is not optimally used mainly because of flushing, a process mediated primarily by prostaglandin D(2), which leads to poor patient compliance and suboptimal dosing...
  74. ncbi [Influence of combined, hypolipemic therapy on lipids and non-lipid atherosclerosis risk factors]
    Marlena Broncel
    Department of Internal Diseases with Clinical Pharmacology and Therapy Monitoring Unit, Medical University of Łódź, Poland
    Pol Merkur Lekarski 22:62-5. 2007
    ..In this article, we briefly review the clinical trial data on the efficacy, safety and influence on non-lipid atherosclerosis factors of combined therapy statin with fibrates, statin with nicotinic acid and statin with ezetimibe...
  75. ncbi [When should an association of lipid-lowering drugs be proposed in a patient failing to reach therapeutic targets under monotherapy? Guidelines of the New French Society of Atherosclerosis]
    M Farnier
    Point Medical, Rond Point de la Nation, 21000 Dijon
    Arch Mal Coeur Vaiss 100:569-81. 2007
  76. ncbi Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins
    Stefania Lamon-Fava
    Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA 02111, USA
    Arterioscler Thromb Vasc Biol 28:1672-8. 2008
    Extended-release niacin effectively lowers plasma TG levels and raises plasma high-density lipoprotein (HDL) cholesterol levels, but the mechanisms responsible for these effects are unclear.
  77. ncbi Management of hyperlipidemia with statins in the older patient
    Wilbert S Aronow
    Department of Medicine, Cardiology and Geriatrics Divisions, New York Medical College, Valhalla, NY 10595, USA
    Clin Interv Aging 1:433-8. 2006
    ..When LDL cholesterol-lowering drug therapy is used to treat high-risk persons or moderately high-risk persons, the serum LDL cholesterol should be decreased at least 30% to 40%...
  78. ncbi Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes
    Madiha Abdel-Maksoud
    Department of Public Health, Preventive, and Social Medicine, Tanta University, Egypt
    J Cardiovasc Pharmacol 51:331-51. 2008
    ..However, randomized clinical trials involving fibrates have not shown consistent benefit. Niacin (nicotinic acid), which is the most effective available medication for raising HDL-C and also lowers triglycerides,..
  79. ncbi Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study
    Richard H Karas
    Division of Cardiology, Molecular Cardiology Research Institute, Tufts Medical Center, Boston, Massachusetts, USA
    Am J Cardiovasc Drugs 8:69-81. 2008
    ..This fact has focused increased attention on treating abnormalities of non-high-density lipoprotein-cholesterol (non-HDL-C), HDL-C, and triglycerides in national guidelines and has intensified interest in combination therapy...
  80. ncbi Treatment of high-risk older persons with lipid-lowering drug therapy
    Wilbert S Aronow
    Department of Medicine, Divisions of Cardiology, Geriatrics, and Pulmonary Critical Care, New York Medical College, Valhalla, NY 10595, USA
    Am J Ther 15:102-7. 2008
    ..High-risk older persons should be treated with lipid-lowering drugs according to the NCEP III updated guidelines to reduce cardiovascular morbidity and mortality...
  81. ncbi Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy
    Tamar S Polonsky
    University of Chicago, Pritzker School of Medicine, Chicago, Illinois 60637 1470, USA
    Am J Cardiol 101:27B-35B. 2008
    ..In this article, the authors review the use of combination therapy as a strategy for risk reduction in CAD...
  82. ncbi Cost-effectiveness of raising HDL cholesterol by adding prolonged-release nicotinic acid to statin therapy in the secondary prevention setting: a French perspective
    S Roze
    CORE Center for Outcomes Research, IMS Health, Allschwil, Switzerland
    Int J Clin Pract 61:1805-11. 2007
    ..To evaluate the cost-effectiveness of raising high-density lipoprotein cholesterol (HDL-C) with add-on nicotinic acid in statin-treated patients with coronary heart disease (CHD) and low HDL-C, from the French healthcare system perspective...
  83. ncbi Treating hypertriglyceridemia
    Bruce J Holub
    CMAJ 177:604; author reply 604-5. 2007
  84. ncbi Treating hypertriglyceridemia
    Georg Roggla
    CMAJ 177:603; author reply 604-5. 2007
  85. ncbi Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system)
    Alawi A Alsheikh Ali
    Molecular Cardiology Research Institute and Division of Cardiology, Tufts New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts, USA
    Am J Cardiol 99:379-81. 2007
    ..Current drug labeling warns of an increased risk of adverse events with statin and niacin combinations. These recommendations have been based solely on case reports...
  86. ncbi Hypertriglyceridemia: its etiology, effects and treatment
    George Yuan
    Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ont
    CMAJ 176:1113-20. 2007
    ..We review the causes and classification of elevated triglyceride levels, the clinical manifestations of primary hypertriglyceridemia and the management of patients with elevated triglyceride levels...
  87. ncbi [Therapy of dyslipidemia in post-infarction: state of the art]
    M C Borgia
    Dipartimento di Scienze Cliniche, Universita Sapienza, Roma, Italia
    Clin Ter 158:523-32. 2007
    ..The innovative therapeutic approach to hypercholesterolemia today is based on a double inhibition of cholesterol synthesis and absorption combining a statin with ezetimibe...
  88. ncbi Safety and tolerability of prolonged-release nicotinic acid in statin-treated patients
    R S Birjmohun
    Academic Medical Center, Amsterdam, The Netherlands
    Curr Med Res Opin 23:1707-13. 2007
    ..To evaluate the safety and tolerability of prolonged-release nicotinic acid (Niaspan) added to statin therapy in patients at increased cardiovascular risk...
  89. ncbi The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease
    Eberhard Windler
    Center of Internal Medicine, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Diab Vasc Dis Res 4:136-42. 2007
    ....
  90. ncbi Managing dyslipidemia in chronic kidney disease
    Charles R Harper
    Department of Medicine, Emory University, Atlanta, Georgia 30303, USA
    J Am Coll Cardiol 51:2375-84. 2008
    ..After reviewing the safety and dose alterations required in managing dyslipidemia in patients with CKD, a practical treatment algorithm is proposed...
  91. ncbi Clinical practice. Hypertriglyceridemia
    John D Brunzell
    Department of Medicine, Division of Metabolism, Endocrinology, and Nutrition, and the Northwest Lipid Metabolism and Diabetes Research Laboratories, University of Washington, Seattle, USA
    N Engl J Med 357:1009-17. 2007
  92. ncbi Treating hypertriglyceridemia
    Irfan Yavasoglu
    CMAJ 177:603-4; author reply 604-5. 2007
  93. ncbi Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia
    John R Guyton
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Am Coll Cardiol 51:1564-72. 2008
    This study evaluated the safety and lipid-altering efficacy of ezetimibe/simvastatin (E/S) coadministered with extended-release niacin (N) in patients with type IIa or IIb hyperlipidemia.
  94. ncbi Patients with low levels of high-density lipoprotein cholesterol: to treat or not to treat?
    S Tavintharan
    Department of Medicine, Alexandra Hospital, 378 Alexandra Road, Singapore 159964
    Singapore Med J 46:519-28. 2005
    ..A number of agents potentially modify HDL favourably. Niacin is the most potent HDL-C raising agent currently available in clinical practice, followed by fibrates...
  95. ncbi [Low HDL-cholesterol, high triglycerides--well known but often ignored]
    R Benz
    Medizinische Poliklinik, Hypertonie und Adipositassprechstunde, Universitatsspital Zurich
    Praxis (Bern 1994) 93:1911-6. 2004
    ..We therefore want to show the relation of the triglyzerides with the HDL-Cholesterol and the nonpharmacologic treatment of these two factors. Some clinical examples are illustrating the topic...
  96. ncbi Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice
    R S Birjmohun
    Department of Vascular Medicine, Academic Medical Centre, PO Box 22660, 1100 DD Amsterdam, The Netherlands
    Neth J Med 62:229-34. 2004
    ..The inverse relation between high-density lipoprotein cholesterol (HDL-C) and cardiovascular (CV) disease underscores the need for clinical evaluation of the effect of HDL-C increasing drugs on the prevalence of CV disease...
  97. ncbi Coadministration of multidrug therapy to achieve lipid goals
    Margo A Denke
    The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78284, USA
    J Am Osteopath Assoc 104:S17-22. 2004
    ..The coadministration of low doses of these agents has been proved to be as effective as high-dose statin therapy in reducing LDL-C levels and assisting patients achieve their treatment goals...
  98. ncbi Existing and investigational combination drug therapy for high-density lipoprotein cholesterol
    Harold Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky 40213, USA
    Am J Cardiol 90:30K-43K. 2002
    ..This more global, multidimensional approach to lipid-altering drug treatment may provide the best chance to prevent CAD...
  99. ncbi Utility of currently available modes of therapy in reaching lipid goals
    Kelly Anne Spratt
    University of Pennsylvania Health System, Cardiovascular Division, Philadelphia Heart Institute, Second Floor, 39th and Market Streets, Philadelphia, PA 19104, USA
    J Am Osteopath Assoc 104:S14-6. 2004
    ..In addition, nonprescription agents such as plant stanols and sterols are available to modify plasma lipid levels. These agents can be used individually or coadministered to achieve lipid goals...
  100. ncbi Use of combination therapy for dyslipidemia: a lipid clinic approach
    Alan S Brown
    Midwest Heart Specialists Disease Prevention Center, Naperville, Illinois 60540, USA
    Am J Cardiol 90:44K-49K. 2002
    ..Approaches to LDL lowering for complex dyslipidemias and management strategies for specific lipid-lowering therapies are provided...
  101. ncbi Combination therapy for dyslipidemia: safety and regulatory considerations
    Michael H Davidson
    Chicago Center for Clinical Research, Rush Medical College, Chicago, Illinois 60612, USA
    Am J Cardiol 90:50K-60K. 2002
    ..lipid-altering therapy often requires the use of combination therapy involving statins in conjunction with niacin, fibric-acid derivatives, ezetimibe, or bile acid resins...

Research Grants69

  1. Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis
    Emmanouil Brilakis; Fiscal Year: 2010
    ..b>Niacin raises HDL-C, restores the re-endothelialization capacity of EPCs, and slowed the progression of SVG ..
  2. Aromatic amino acid metabolism in the pathogenesis of kwashiorkor
    Farook Jahoor; Fiscal Year: 2007
    ..are precursors for dopamine, melanin and the catecholamines, and tryptophan is the precursor of serotonin and niacin, a shortage of the AAAs may underlie most of the signs and symptoms of kwashiorkor...
  3. LIPOGENESIS & LIPOPROTEIN COMPLICATIONS OF HIV THERAPY
    David Hui; Fiscal Year: 2004
    ..The potential beneficial effects of niacin, due to its proteasome-independent stimulation of apoB degradation, will also be explored...
  4. Discovery and Preclinical Development of Drugs for Anthrax, Plague and Tularemia
    Christie Brouillette; Fiscal Year: 2007
    ..These diseases are caused by three of the highest risk bacterial bioterrorism agents, B. anthracis, Y. pestis, and F. tularensis. ..
  5. Comprehensive Magnetic Resonance in PAD
    Christopher M Kramer; Fiscal Year: 2010
    ..Aim 3 is to use comprehensive MR to test the efficacy of raising HDL with a novel formulation of niacin with laropiprant that reduces flushing compared to placebo in mild to moderate PAD...
  6. OMEGA-3 FATTY ACIDS IN BIPOLAR DISORDER PROPHYLAXIS
    ANDREW STOLL; Fiscal Year: 2002
    ..Plasma and erythrocyte fatty acid content. 2. The niacin skin patch test (a possible marker of in vivo omega-3 fatty acid activity). 3...
  7. MECHANISMS OF ENZYMATIC REACTIONS
    PERRY FREY; Fiscal Year: 2002
    ..in studies of Ga1E will be to describe the molecular basis for the enhancement of the chemical reactivity of the niacin- co-enzyme NAD+ by the use of binding energy between the UDP-moiety of substrates and the enzyme...
  8. HDL AND PLAQUES--NOVEL MODELS AND IMAGING TECHNIQUES
    Edward Fisher; Fiscal Year: 2001
    ..Plasma lipid levels will be modified by therapy with a statin or statin plus niacin (to raise HDL) and changes in plaque size and composition will be followed serially by MRI...
  9. Niacin, n-3 fatty acids and insulin resistance
    William Harris; Fiscal Year: 2006
    ..In recent studies from our laboratory, niacin and fish oil (n-3 fatty acids, FA) used in combination in individuals with the IRS improved the lipid phenotype, ..
  10. Niacin, n-3 fatty acids and insulin resistance
    William Harris; Fiscal Year: 2007
    ..In recent studies from our laboratory, niacin and fish oil (n-3 fatty acids, FA) used in combination in individuals with the IRS improved the lipid phenotype, ..
  11. MODE OF ACTION OF PYRAZINAMIDE IN TUBERCLE BACILLUS
    Ying Zhang; Fiscal Year: 2003
    ..Because of structural similarity of POA to niacin, they hypothesize that POA may interfere with NAD metabolism in M...
  12. MODE OF ACTION OF PYRAZINAMIDE IN TUBERCLE BACILLUS
    Ying Zhang; Fiscal Year: 1999
    ..Because of structural similarity of POA to niacin, they hypothesize that POA may interfere with NAD metabolism in M...
  13. A Transdermal Hypolipidemic Niacin Prodrug
    Hyuntae Kim; Fiscal Year: 2002
    b>Niacin has been used as first-line drug therapy for elevated serum cholesterol because of its broad efficacy on multiple lipid components as well as its low cost...
  14. A Trial of Zinc and Micronutrients in Tanzanian Children
    Christopher P Duggan; Fiscal Year: 2010
    ..be recruited and randomly assigned in a factorial design to either zinc, micronutrients (vitamins C, E, B1, B2, niacin, B6, folate, and B12) plus zinc, micronutrients without zinc, or a placebo given daily...
  15. Diet/Exercise, Niacin, Fenofibrate for HIV Lipodystrophy
    Ashok Balasubramanyam; Fiscal Year: 2007
    ..fat mass and improve hormonal, metabolic and lipoprotein markers associated with insulin resistance; and 2) adding niacin, fenofibrate, or a combination of the two drugs to the intensive lifestyle intervention will result in further ..
  16. Diet/Exercise, Niacin, Fenofibrate for HIV Lipodystrophy
    Ashok Balasubramanyam; Fiscal Year: 2007
    ..fat mass and improve hormonal, metabolic and lipoprotein markers associated with insulin resistance; and 2) adding niacin, fenofibrate, or a combination of the two drugs to the intensive lifestyle intervention will result in further ..
  17. A Trial of Zinc and Micronutrients in Tanzanian Children
    Christopher Duggan; Fiscal Year: 2007
    ..be recruited and randomly assigned in a factorial design to either zinc, micronutrients (vitamins C, E, B1, B2, niacin, B6, folate, and B12) plus zinc, micronutrients without zinc, or a placebo given daily...
  18. MECHANISMS OF ENZYMATIC REACTIONS
    PERRY FREY; Fiscal Year: 2006
    ..of epimerase will be to elucidate the molecular basis for the enhancement of the chemical reactivity of the niacin-coenzyme NAD+ by the use of binding energy between substrates and the enzyme...
  19. Monitoring Oxygen Repeatedly for Hypoxic Tumor Therapy
    Mohammad Khan; Fiscal Year: 2007
    ..The proposed approach to modulate tumor hypoxia will avoid possible complications and toxicity arising due to oral or injections of drugs. If successful, this approach potentially could be immediately extended for clinical applications. ..